Nonetheless, ERBB signal inhibitors have demonstrated promising efficacy in clinical trials across multiple tumor types, including GC and esophageal cancer.[38,39] Further research and clinical investigation are warranted to elucidate their exact role and therapeutic efficacy in the management of this specific subtype of cancer. This evidence concerns the gene EGFR and cancer.